Research Radar — 2026-08-15
Biomedical discoveries
Biomedicine
Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers
Nature Communications Published 2026-08-14 Research article DOI: 10.1038/s41467-026-76718-7
CAR-iNKT cells multiple myeloma bispecific engagers cancer immunotherapy
Summary: The study identifies a BCMA CD28ζ CAR design with high anti-myeloma activity in iNKT cells, then combines CAR-iNKT therapy with a BCMA-specific iNKT engager; dual FCRL5 CAR-iNKT and BCMA-engager treatment further limits antigen-negative immune escape.
Why it matters: It provides a concrete dual-target, dual-modality strategy for improving engineered-cell activity and addressing antigen-loss escape in multiple myeloma.
Why for Yiru: This is directly relevant to computational immunology and oncology, particularly for connecting cell-state-aware immune design with engineered cell therapies.
A permeable protein nanocage enables facile cargo loading and cytosolic protein delivery
Nature Communications Published 2026-08-14 Research article DOI: 10.1038/s41467-026-76849-x
protein delivery encapsulin nanocages cytosolic delivery therapeutic engineering
Summary: The authors characterize the permeable encapsulin nanocage QtEnc, which permits rapid post-assembly loading of proteins up to 482 kDa, and develop a modular nanocarrier that releases cargo at low pH and supports endosomal escape for cytosolic delivery in HeLa cells.
Why it matters: The platform addresses a major delivery bottleneck for intracellular protein therapeutics by separating modular cargo loading, release, and endosomal-escape functions.
Why for Yiru: Its modular cargo-platform design is transferable to drug discovery and therapeutic engineering, including intracellular biologics development.